Todd M. Bauer

16.7k citations

264 papers · 8.6k indexed · 6 hit papers · h-index 50

Oncology top 0.2%
Pulmonary and Respiratory Medicine top 0.2%
Molecular Biology top 2%
Cancer Research top 1%
Immunology top 2%

Co-authors: Alice T. Shaw Benjamin Solomon Enriqueta Felip Holger Thurm Manish R. Patel Gerson Peltz Benjamin Besse Antonello Abbattista
Topics: Lung Cancer Treatments and Mutations (77 papers)Cancer Immunotherapy and Biomarkers (53 papers)Lung Cancer Research Studies (34 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: New England Journal of Medicine Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: United States France Italy

In The Last Decade

Todd M. Bauer

251 papers receiving 8.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

2020 649 citations Alice T. Shaw, Todd M. Bauer et al. New England Journal of Medicine profile →
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

2017 487 citations Alice T. Shaw, Enriqueta Felip et al. profile →
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

2019 269 citations Alice T. Shaw, Benjamin Solomon et al. Journal of Clinical Oncology profile →
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

2021 196 citations Todd M. Bauer et al. profile →
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Todd M. Bauer et al. profile →
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Todd M. Bauer

Since Specialization

Citations

This map shows the geographic impact of Todd M. Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd M. Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd M. Bauer more than expected).

Fields of papers citing papers by Todd M. Bauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd M. Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd M. Bauer. The network helps show where Todd M. Bauer may publish in the future.

Co-authorship network of co-authors of Todd M. Bauer

This figure shows the co-authorship network connecting the top 25 collaborators of Todd M. Bauer. A scholar is included among the top collaborators of Todd M. Bauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd M. Bauer. Todd M. Bauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: results of the glioblastoma expansion cohort 2025 ·Neuro-Oncology Advances ·Roy E. Strowd,Macarena de la Fuente,Todd M. Bauer,Kyriakos P. Papadopoulos,Ke Chen,Rodolfo F. Perini,Yanfang Liu,David F. McDermott	0
2	Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study 2025 ·PubMed ·Aung Naing,Amit Mahipal,Milind Javle,Judy Wang,Todd M. Bauer,David L. Bajor,Anthony Elias,Anthony F. Shields,Elizabeth J. Davis,Sant P. Chawla,(unknown),John D. Powderly,Gina Z. D’Amato,Christian F. Meyer,Xiongwen Tang,Sheng Yao,Patricia Keegan	0
3	First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors 2025 ·Journal for ImmunoTherapy of Cancer ·Michele Maio,Víctor Moreno,Juan Martín-Liberal,Frans L. Opdam,Aaron R. Hansen,Todd M. Bauer,Christophe Le Tourneau,Antoîne Italiano,Danny Rischin,Catherine Ellis,David C. Turner,Sapna Yadavilli,(unknown),Steven Hirschfeld,Marc Ballas,Iván Díaz-Padilla,Eric Angevin	1
4	Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Studybreakdown → 2024 ·Journal of Clinical Oncology ·Benjamin Solomon,Geoffrey Liu,Enriqueta Felip,Tony Mok,Ross A. Soo,Julien Mazières,Alice T. Shaw,Filippo de Marinis,Yasushi Goto,Yi‐Long Wu,Dong‐Wan Kim,Jean-François Martini,Rossella Messina,Jolanda Paolini,Anna Polli,Despina Thomaidou,Francesca Toffalorio,Todd M. Bauer	118
5	The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study 2023 ·Cancer Discovery ·Patricia LoRusso,Noboru Yamamoto,Manish R. Patel,Scott A. Laurie,Todd M. Bauer,(unknown),(unknown),(unknown),(unknown),(unknown),Mrinal M. Gounder	55
6	First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma 2023 ·Molecular Cancer Therapeutics ·Erika Hamilton,Judy S. Wang,Amit M. Oza,Manish R. Patel,Susanna V. Ulahannan,Todd M. Bauer,Janet L. Karlix,Jorge Zerón-Medina,(unknown),Paola Marco‐Casanova,Ganesh Moorthy,Maureen M. Hattersley,(unknown),Pat Mitchell,Jamal Saeh,Gayle P. Pouliot,Kathleen N. Moore	14
7	A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors 2023 ·Targeted Oncology ·Todd M. Bauer,Kathleen N. Moore,Janet S. Rader,Fiona Simpkins,Alain C. Mita,J. Thaddeus Beck,Lowell L. Hart,Quincy S. Chu,Amit M. Oza,Anna V. Tinker,(unknown),Sanjeev Kumar,Ganesh Mugundu,Suzanne Jenkins,Juliann Chmielecki,Suzanne F. Jones,David R. Spigel,Siqing Fu	21
8	Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study 2023 ·Journal for ImmunoTherapy of Cancer ·Omid Hamid,Jessica C. Hassel,Alexander N. Shoushtari,Friedegund Meier,Todd M. Bauer,April K.S. Salama,John M. Kirkwood,Paolo A. Ascierto,Paul Lorigan,Cornelia Mauch,Marlana Orloff,T.R. Jeffry Evans,Chris Holland,(unknown),(unknown),Mark R. Middleton	22
9	Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors 2022 ·Clinical Cancer Research ·Jonathan W. Goldman,Sarina A. Piha‐Paul,Brendan D. Curti,Katrina S. Pedersen,Todd M. Bauer,Stefanie L. Groenland,Richard D. Carvajal,(unknown),(unknown),Kelly McGlinchey,Scott A. Hammond,Katie Streicher,Danielle M. Townsley,Young Kwang Chae,Jens Voortman,Aurélien Marabelle,John D. Powderly	19
10	Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors 2022 ·Clinical Cancer Research ·Diwakar Davar,Roberta Zappasodi,Hong Wang,Girish S. Naik,Takami Sato,Todd M. Bauer,David L. Bajor,Olivier Rixe,Walter Newman,Jingjing Qi,(unknown),Phillip Wong,(unknown),(unknown),Cynthia A. Sirard,Taha Merghoub,Jedd D. Wolchok,Jason J. Luke	37
11	Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors 2022 ·Clinical Cancer Research ·Emerson A. Lim,Johanna C. Bendell,Gerald S. Falchook,Todd M. Bauer,Charles G. Drake,Jennifer H. Choe,Daniel J. George,Janet L. Karlix,Susanna V. Ulahannan,Kris F. Sachsenmeier,Deanna L. Russell,Ganesh Moorthy,Ben S. Sidders,Elizabeth A. Pilling,(unknown),Maureen M. Hattersley,Mayukh Das,Rakesh Kumar,Gayle P. Pouliot,Manish R. Patel	55
12	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma 2021 ·Clinical Cancer Research ·D. Ross Camidge,Daniel Morgensztern,Rebecca S. Heist,Minal Barve,Everett E. Vokes,Jonathan W. Goldman,David S. Hong,Todd M. Bauer,John H. Strickler,Eric Angevin,Monica Motwani,Apurvasena Parikh,Zhaowen Sun,Bruce Allen Bach,Jun Wu,Philip Komarnitsky,Karen Kelly	60
13	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer 2021 ·Prostate Cancer and Prostatic Diseases ·Charles G. Drake,Russell K. Pachynski,Sumit K. Subudhi,Douglas G. McNeel,Emmanuel S. Antonarakis,Todd M. Bauer,Peter Lauer,Dirk G. Brockstedt,(unknown),Mark Wade,Enrique Zudaire,Nibedita Bandyopadhyay,Dolly A. Parasrampuria,Suzette Girgis,Gary Mason,Roland E. Knoblauch,Nicole L. Stone,Jeffrey R. Infante,Marco M. Gottardis,Lawrence Fong	28
14	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 2021 ·Clinical Cancer Research ·Mansoor N. Saleh,Manish R. Patel,Todd M. Bauer,Sanjay Goel,Gerald S. Falchook,Geoffrey I. Shapiro,Ki Y. Chung,Jeffrey R. Infante,Robert M. Conry,Guilherme Rabinowits,David S. Hong,Judy S. Wang,Ulrich Steidl,Gurudatta Naik,Vincent Guerlavais,Vojislav Vukovic,D. Allen Annis,Manuel Aivado,Funda Meric‐Bernstam	110
15	First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancerbreakdown → 2020 ·New England Journal of Medicine ·Alice T. Shaw,Todd M. Bauer,Filippo de Marinis,Enriqueta Felip,Yasushi Goto,Geoffrey Liu,Julien Mazières,Dong‐Wan Kim,Tony Mok,Anna Polli,Holger Thurm,Anna Maria Calella,Gerson Peltz,Benjamin Solomon	649
16	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer 2019 ·Clinical Cancer Research ·James J. Harding,Andrew X. Zhu,Todd M. Bauer,Toni K. Choueiri,Alexander Drilon,Martin H. Voss,Charles S. Fuchs,Ghassan K. Abou‐Alfa,Sameera R. Wijayawardana,Xuejing Aimee Wang,Brian A. Moser,(unknown),Volker Wacheck,Johanna C. Bendell	32
17	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer 2019 ·Breast Cancer Research and Treatment ·Vandana G. Abramson,Mafalda Oliveira,Andrés Cervantes,Hans Wildiers,Manish R. Patel,Todd M. Bauer,Philippe L. Bédard,Carlos Becerra,Stephen Richey,Michael C. Wei,Eric L. Reyner,John H. Bond,Na Cui,Timothy R. Wilson,Heather M. Moore,Cristina Saura,Ian E. Krop	4
18	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer 2018 ·Clinical Cancer Research ·Johanna C. Bendell,Anna M. Varghese,David M. Hyman,Todd M. Bauer,Shubham Pant,Sophie Callies,Ji Lin,Ricardo Martínez,Enaksha Wickremsinhe,(unknown),Volker Wacheck,Kathleen N. Moore	81
19	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors 2018 ·Journal of Clinical Oncology ·John H. Strickler,Colin D. Weekes,John Nemunaitis,Ramesh K. Ramanathan,Rebecca S. Heist,Daniel Morgensztern,Eric Angevin,Todd M. Bauer,Huibin Yue,Monica Motwani,Apurvasena Parikh,Edward B. Reilly,Daniel Afar,Louie Naumovski,Karen Kelly	104
20	Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors 2016 ·Clinical Cancer Research ·Jeffrey R. Infante,Antoine Hollebecque,Sophie Postel‐Vinay,Todd M. Bauer,Elizabeth M. Blackwood,Marie Evangelista,Sami Mahrus,Franklin Peale,Xuyang Lu,Srikumar Sahasranaman,Rui Zhu,Yuan Chen,Xiao Ding,Elaine Murray,Jennifer L. Schutzman,Jennifer Lauchle,Jean‐Charles Soria,Patricia LoRusso	59

About Todd M. Bauer

Todd M. Bauer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 264 papers that have together received 8.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (77 papers), Cancer Immunotherapy and Biomarkers (53 papers) and Lung Cancer Research Studies (34 papers). The work is most often cited by research in Oncology (5.4k citations), Pulmonary and Respiratory Medicine (4.2k citations) and Cancer Research (1.5k citations). Todd M. Bauer has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Alice T. Shaw, Benjamin Solomon, Enriqueta Felip, Holger Thurm, Manish R. Patel, Gerson Peltz, Benjamin Besse, Antonello Abbattista, Jeffrey R. Infante and Jill S. Clancy. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact